Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

At this time, this protocol is recruiting patients for Cervical Cancer and Merkel Cell Carcinoma only.

Recruiting

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors - CA209-358

Updated: 17 October, 2018   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participants Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page CA209-358
Download Study Participants Guide

SELECT LANGUAGE

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 24

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Metastatic Monotherapy Cohort
Drug: Nivolumab
Experimental: Neoadjuvant Cohort
Drug: Nivolumab
Experimental: Nivolumab plus Daratumumab Cohort
Drug: Daratumumab Drug: Nivolumab
Experimental: Nivolumab plus Ipilimumab Cohort
Drug: Ipilimumab Drug: Nivolumab
Experimental: Nivolumab plus Relatlimab Cohort
Drug: Relatlimab Drug: Nivolumab

Key Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types): 1. Merkel Cell Carcinoma 2. Gastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type) 3. Nasopharyngeal Carcinoma 4. Squamous cell carcinoma (SCC) of the cervix, vagina, or vulva 5. Squamous cell carcinoma of the Head and Neck 6. Squamous cell carcinoma of the anal canal and penis 7. Recurrent/metastatic SCC of the cervix not amenable to curative treatment with surgery and/or radiation therapy who are unsuitable for platinum-based therapy may enroll in the cervical cancer Combination B expansion cohort - Measurable disease by CT or MRI - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen) - Men and women of age 18 or older Exclusion Criteria: - Active brain metastases or leptomeningeal metastases - Patients with active, known or suspected autoimmune disease - Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications - Patients with hepatitis - Patients with HIV - Pregnant or breastfeeding women

Have questions? Email Us

Have questions?
Email Us